PDF(Pubmed)
Abstract：
BACKGROUND: The work-up and diagnosis of indeterminate lung nodules at time of bladder cancer diagnosis may delay or change treatment.
OBJECTIVE: To quantify the incidence of synchronous and metachronous lung cancers in adults with bladder cancer and compare these rates to the incidence of bladder cancer metastases in the lung.
METHODS: We retrospectively analyzed all adults diagnosed with bladder cancer in the Surveillance, Epidemiology and End Results (SEER) registry (2010- 2015) and identified second primary lung cancers defined as being either synchronous (diagnosed within 6 months of bladder cancer diagnosis) or metachronous (more than 6 months following index bladder cancer diagnosis). The risk of second primary lung cancers were reported as a standardized incidence ratio (SIR) reflecting observed and expected case ratios.
RESULTS: A total of 88,335 patients diagnosed with bladder cancer were included. Among adults with NMIBC (n = 66,071) and MIBC (n = 18,879), 0.3% and 3.9% had bladder cancer metastatic to the lungs at diagnosis. Synchronous second primary lung cancers were diagnosed in 0.4% and 0.7% of patients with NMIBC and MIBC, respectively. Compared to the general population, the SIR for synchronous lung cancers among adults with NMIBC was 2.5 (95% CI 2.3- 2.9) and was 4.7 (95% CI 4.0- 5.6) for adults with MIBC.
CONCLUSIONS: Bladder cancer metastatic to the lung is more common in adults with MIBC compared to NMIBC. There are similar frequencies of synchronous second primary lung cancers regardless of initial bladder cancer stage.
OBJECTIVE: To quantify the incidence of synchronous and metachronous lung cancers in adults with bladder cancer and compare these rates to the incidence of bladder cancer metastases in the lung.
METHODS: We retrospectively analyzed all adults diagnosed with bladder cancer in the Surveillance, Epidemiology and End Results (SEER) registry (2010- 2015) and identified second primary lung cancers defined as being either synchronous (diagnosed within 6 months of bladder cancer diagnosis) or metachronous (more than 6 months following index bladder cancer diagnosis). The risk of second primary lung cancers were reported as a standardized incidence ratio (SIR) reflecting observed and expected case ratios.
RESULTS: A total of 88,335 patients diagnosed with bladder cancer were included. Among adults with NMIBC (n = 66,071) and MIBC (n = 18,879), 0.3% and 3.9% had bladder cancer metastatic to the lungs at diagnosis. Synchronous second primary lung cancers were diagnosed in 0.4% and 0.7% of patients with NMIBC and MIBC, respectively. Compared to the general population, the SIR for synchronous lung cancers among adults with NMIBC was 2.5 (95% CI 2.3- 2.9) and was 4.7 (95% CI 4.0- 5.6) for adults with MIBC.
CONCLUSIONS: Bladder cancer metastatic to the lung is more common in adults with MIBC compared to NMIBC. There are similar frequencies of synchronous second primary lung cancers regardless of initial bladder cancer stage.
摘要：
背景：膀胱癌诊断时不确定的肺结节的检查和诊断可能会延迟或改变治疗。
目的：量化成人膀胱癌中同步性和异时性肺癌的发生率，并将这些发生率与肺癌中膀胱癌转移的发生率进行比较。
方法：我们回顾性分析了在监测中诊断为膀胱癌的所有成年人，流行病学和最终结果（SEER）注册（2010-2015），并确定了第二原发性肺癌，其定义为同步（在膀胱癌诊断的6个月内诊断）或异时（在膀胱癌诊断后超过6个月）。第二原发性肺癌的风险报告为反映观察到的和预期的病例比的标准化发病率比(SIR)。
结果：共88,335例诊断为膀胱癌的患者。在患有NMIBC（n=66,071）和MIBC（n=18,879）的成年人中，0.3%和3.9%的膀胱癌在诊断时转移到肺部。在NMIBC和MIBC患者中，有0.4％和0.7％的同步第二原发性肺癌被诊断出，分别。与普通人群相比，NMIBC成人同步肺癌的SIR为2.5(95%CI2.3-2.9),MIBC成人为4.7(95%CI4.0-5.6).
结论：与NMIBC相比，在成人MIBC患者中转移到肺的膀胱癌更为常见。无论初始膀胱癌阶段如何，同步第二原发性肺癌的频率都相似。
目的：量化成人膀胱癌中同步性和异时性肺癌的发生率，并将这些发生率与肺癌中膀胱癌转移的发生率进行比较。
方法：我们回顾性分析了在监测中诊断为膀胱癌的所有成年人，流行病学和最终结果（SEER）注册（2010-2015），并确定了第二原发性肺癌，其定义为同步（在膀胱癌诊断的6个月内诊断）或异时（在膀胱癌诊断后超过6个月）。第二原发性肺癌的风险报告为反映观察到的和预期的病例比的标准化发病率比(SIR)。
结果：共88,335例诊断为膀胱癌的患者。在患有NMIBC（n=66,071）和MIBC（n=18,879）的成年人中，0.3%和3.9%的膀胱癌在诊断时转移到肺部。在NMIBC和MIBC患者中，有0.4％和0.7％的同步第二原发性肺癌被诊断出，分别。与普通人群相比，NMIBC成人同步肺癌的SIR为2.5(95%CI2.3-2.9),MIBC成人为4.7(95%CI4.0-5.6).
结论：与NMIBC相比，在成人MIBC患者中转移到肺的膀胱癌更为常见。无论初始膀胱癌阶段如何，同步第二原发性肺癌的频率都相似。
